10,726 Shares in Lexeo Therapeutics, Inc. $LXEO Purchased by Ethic Inc.

Ethic Inc. acquired a new position in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 10,726 shares of the company’s stock, valued at approximately $44,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of LXEO. Privium Fund Management B.V. increased its stake in shares of Lexeo Therapeutics by 11.3% during the second quarter. Privium Fund Management B.V. now owns 178,356 shares of the company’s stock valued at $753,000 after purchasing an additional 18,158 shares in the last quarter. CWM LLC grew its stake in shares of Lexeo Therapeutics by 150.3% in the 2nd quarter. CWM LLC now owns 10,351 shares of the company’s stock worth $42,000 after buying an additional 6,216 shares during the last quarter. Vanguard Personalized Indexing Management LLC bought a new position in Lexeo Therapeutics during the 2nd quarter valued at approximately $60,000. Palumbo Wealth Management LLC bought a new position in Lexeo Therapeutics during the 2nd quarter valued at approximately $226,000. Finally, Rhumbline Advisers raised its stake in Lexeo Therapeutics by 19.8% during the first quarter. Rhumbline Advisers now owns 30,192 shares of the company’s stock valued at $105,000 after buying an additional 4,995 shares during the last quarter. Hedge funds and other institutional investors own 60.67% of the company’s stock.

Lexeo Therapeutics Price Performance

NASDAQ LXEO opened at $10.01 on Friday. The stock has a market capitalization of $540.54 million, a price-to-earnings ratio of -3.07 and a beta of 1.66. Lexeo Therapeutics, Inc. has a 1-year low of $1.45 and a 1-year high of $11.72. The business’s fifty day moving average price is $6.87 and its 200-day moving average price is $4.91.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.04. Equities research analysts anticipate that Lexeo Therapeutics, Inc. will post -3.14 EPS for the current year.

Insider Buying and Selling at Lexeo Therapeutics

In related news, insider Tai Sandi See sold 3,888 shares of the firm’s stock in a transaction that occurred on Friday, October 17th. The shares were sold at an average price of $8.94, for a total value of $34,758.72. Following the transaction, the insider owned 65,862 shares of the company’s stock, valued at approximately $588,806.28. This trade represents a 5.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Eric Adler sold 3,382 shares of the business’s stock in a transaction that occurred on Friday, October 17th. The shares were sold at an average price of $8.94, for a total transaction of $30,235.08. Following the sale, the insider owned 73,261 shares of the company’s stock, valued at $654,953.34. This trade represents a 4.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 29,091 shares of company stock worth $232,007 in the last three months. 5.30% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have recently commented on LXEO shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Lexeo Therapeutics in a research note on Wednesday, October 8th. Guggenheim started coverage on shares of Lexeo Therapeutics in a research report on Wednesday, October 15th. They set a “buy” rating and a $30.00 price objective on the stock. Chardan Capital raised their price objective on shares of Lexeo Therapeutics from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Tuesday, October 7th. HC Wainwright decreased their target price on shares of Lexeo Therapeutics from $15.00 to $13.00 and set a “buy” rating for the company in a report on Tuesday, October 21st. Finally, Leerink Partners increased their price target on shares of Lexeo Therapeutics from $9.00 to $20.00 and gave the company an “outperform” rating in a report on Tuesday, October 7th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $18.57.

Lexeo Therapeutics Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.